Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.78 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.72 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meglitinide SCHEMBL29829482 | 1.00 | DNMT3A (0.78) | DNMT3AHDAC1HDAC6NLRP3GAA | |
| SCHEMBL11354611 | 0.91 | DNMT3A (0.75) | DNMT3AHDAC1HDAC6NLRP3GAA | |
| SCHEMBL11360335 | 0.91 | DNMT3A (0.78) | DNMT3AHDAC1HDAC6NLRP3GAA | |
| SCHEMBL11479096 | 0.90 | HDAC1 (0.71) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL1153776 | 0.90 | DNMT3A (0.67) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL3784241 | 0.89 | DNMT3A (0.80) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL8261934 | 0.89 | DNMT3A (0.84) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL1154792 | 0.88 | DNMT3A (0.62) | DNMT3AHDAC1HDAC6NLRP3GAA | |
| SCHEMBL30381560 | 0.88 | HDAC1 (0.79) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL11481071 | 0.88 | HDAC1 (0.79) | DNMT3AHDAC1HDAC6NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12491 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115210-A1 | METHOD FOR TREATING SUBJECTS SUFFERING FROM CENTRAL NERVOUS SYSTEM CONTUSIONS | REMEDY PHARMACEUTICALS, INC. (US) | 2026-04-30 | — | — | US | claimed |
| EP-3634453-B1 | PLANT EXTRACTS WITH ANTI-DIABETIC AND OTHER USEFUL ACTIVITIES | HOUSEY PHARMACEUTICAL RES LABORATORIES L L C (US) | 2026-04-29 | — | — | EP | claimed |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | claimed |
| US-12611416-B2 | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema | REMEDY PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | claimed |
| US-12599564-B2 | Antidiabetic pharmaceutical compositions | Elite Pharmaceutical Solution Inc. (US) | 2026-04-14 | — | — | US | claimed |
| US-20260069550-A1 | TRANSDERMAL DELIVERY OF ANTIDIABETIC AGENTS | RITTENHOUSE CHRISTINE (US) | 2026-03-12 | — | — | US | claimed |
| EP-4705280-A1 | DIARYL UREA-BASED COMPOUNDS AND RELATED COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DIABETES MELLITUS AND NEURODEGENERATIVE DISEASE | Purdue Research Foundation (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4699609-A2 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | TUFTS MEDICAL CENTER, INC. (US) | 2026-01-20 | — | — | US | claimed |
| US-20250381199-A1 | PHARMACEUTICAL PREPARATION FOR IMPROVING ABSORPTION AND POSTPRANDIAL HYPOGLYCEMIC ACTION OF INSULIN | LILLY CO ELI (US) | 2025-12-18 | — | — | US | claimed |
| WO-2001055085-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | claimed |
| WO-2001055086-A1 | ALKYNYLSUBSTITUTED PROPIONIC ACID DERIVATIVES AND THEIR USE AGAINST DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | claimed |
| WO-2001032158-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF METFORMIN AND ANOTHER ANTIDIABETIC AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-05-10 | — | — | WO | claimed |
| WO-2001027128-A1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-19 | — | — | WO | claimed |
| WO-2001027107-A2 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-19 | — | — | WO | claimed |
| EP-1088824-A2 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| WO-2001021602-A1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-03-29 | — | — | WO | claimed |
| WO-2000059506-A1 | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB CO. (US) | 2000-10-12 | — | — | WO | claimed |
| WO-2000015229-A1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | claimed |
| US-4221815-A | HYPOGLYCEMIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-09-09 | — | — | US | claimed |